首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   668096篇
  免费   55228篇
  国内免费   20080篇
耳鼻咽喉   5961篇
儿科学   15400篇
妇产科学   10664篇
基础医学   84841篇
口腔科学   13849篇
临床医学   59967篇
内科学   98900篇
皮肤病学   9899篇
神经病学   45268篇
特种医学   14750篇
外国民族医学   135篇
外科学   59209篇
综合类   95837篇
现状与发展   68篇
一般理论   33篇
预防医学   48554篇
眼科学   8847篇
药学   79806篇
  431篇
中国医学   42479篇
肿瘤学   48506篇
  2023年   10531篇
  2022年   14633篇
  2021年   26716篇
  2020年   24705篇
  2019年   28518篇
  2018年   26345篇
  2017年   24084篇
  2016年   22159篇
  2015年   23819篇
  2014年   40294篇
  2013年   45006篇
  2012年   38630篇
  2011年   43634篇
  2010年   36185篇
  2009年   34789篇
  2008年   33602篇
  2007年   32232篇
  2006年   28656篇
  2005年   24847篇
  2004年   20754篇
  2003年   18044篇
  2002年   14204篇
  2001年   12380篇
  2000年   10228篇
  1999年   8866篇
  1998年   6926篇
  1997年   6608篇
  1996年   5692篇
  1995年   5824篇
  1994年   5331篇
  1993年   4421篇
  1992年   4052篇
  1991年   3602篇
  1990年   3117篇
  1989年   2665篇
  1988年   2467篇
  1987年   2045篇
  1986年   1973篇
  1985年   5045篇
  1984年   5957篇
  1983年   4162篇
  1982年   4669篇
  1981年   4239篇
  1980年   3730篇
  1979年   3357篇
  1978年   2867篇
  1977年   2192篇
  1976年   2395篇
  1975年   1803篇
  1974年   1542篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
BackgroundMigraine is one of the neurological diseases that have a negative impact on subjects’ productivity and daily activity of patients. Introducing monoclonal antibodies as a valuable option for resolving the persistent problem of migraine is still under investigation. The current study aimed to evaluate the efficacy and safety profile related to Erenumab.MethodsA prospective study for clinical data collection and analysis from recruited therapy-refractory migraine subjects were carried through 6 months for each subject. All subjects received Erenumab 70 mg monthly. Each patient provided the clinical data monthly starting from 0 months and for the next 6 months. Migraine disability assessment (MIDAS) questionnaire was used for evaluation of the Erenumab efficacy every 3 months. In addition, data regarding adverse effects, migraine triggers, and the impact of previous COVID-19 on migraine severity were collected and analyzed.ResultsNinety subjects were recruited in the study. Erenumab injections resulted in a significant (p < 0.001) reduction in MIDAS score in the 3rd month compared with baseline, also this significance was continuous in the 6th month. In contrast, there was no significant difference in the 6th month compared with the 3rd. Previously infected COVID-19 subjects showed a higher severity of migraine attacks compared with non-infected subjects. Skin redness and local pain were the most common adverse effects 63.3%, 47.77% respectively associated with Erenumab.ConclusionUsing Erenumab therapy showed a great beneficial impact regarding the reduction of migraine-related disabilities. COVID-19 was related to the increased severity of migraine attacks.  相似文献   
32.
33.
Mixed lineage leukemia 1(MLL1)是组蛋白甲基转移酶SET家族的成员之一。MLL1与WDR5、RbBP5、Ash2L和DPY-30组成MLL1甲基转移酶复合物调控组蛋白H3的第4位赖氨酸的甲基化水平,对造血系统的发育和血细胞的更新至关重要。部分白血病患者体内存在因MLL1基因易位而产生的致癌蛋白——MLL1融合蛋白,MLL1融合蛋白在发挥其致癌作用时需要功能完整的MLL1酶复合物,故靶向MLL1-WDR5的蛋白-蛋白相互作用成为治疗MLL1融合型白血病的潜在策略。本文对MLL1-WDR5蛋白-蛋白相互作用的生物学机制、结构信息以及抑制剂进行了系统的总结,并结合已报道数据对该领域进行了展望,以期为后续研究提供参考。  相似文献   
34.
Transient stress hyperglycemia in the setting of acute myocardial infarction is a frequent phenomenon. Its transient nature should not dissuade the clinician from management of elevated blood glucose in a patient after an ST-elevation myocardial infarction. This case presents an adult patient after an ST-elevation myocardial infarction with transient stress hyperglycemia and the evidence used to identify optimal pharmacologic management and secondary prevention.  相似文献   
35.
《Molecular therapy》2022,30(5):1952-1965
  1. Download : Download high-res image (199KB)
  2. Download : Download full-size image
  相似文献   
36.
From the early days of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there were concerns that nebulizers used for the treatment of respiratory diseases as aerosol-generating devices could enhance the transmission of SARS-CoV-2. However, given the absence of any compelling data showing that nebulized treatments increase the risk of SARS-CoV-2 infection, it is unnecessary for community-dwelling patients with respiratory diseases to alter their current therapies, including nebulized treatments, to prevent symptom exacerbations. Maintaining current inhaled therapies also minimizes the risk of hospitalization and hospital-acquired infection of SARS-CoV-2.  相似文献   
37.
38.
39.
40.
ObjectiveThe aim of this study was to determine whether there is a difference in postural control between nulligravida women and women who have given birth by vaginal or cesarean section.MethodsWomen who had only vaginal delivery in the previous 1–3 years were included in the vaginal delivery group (n = 27), those who had only cesarean delivery in the previous 1–3 years were included in the cesarean section group (n = 28), and those who had never given birth were included in the control group (n = 32). Evaluations were administered 6–8 days after the ovulation phase. Postural control of the participants was evaluated with the computerized dynamic posturography device.ResultsA total of 87 women with a mean age of 29.4 ± 4 years and a mean body mass index of 24.1 ± 3.1 kg/m2 were included in the study. Antero-posterior somatosensory organization test values of the vaginal delivery group were lower than the control group (p = 0.0016). The cesarean delivery group had statistically lower antero-posterior somatosensory (p < 0.001 and p = 0.0013) and medio-lateral somatosensory (p = 0.002 and p = 0.017, respectively) test scores compared to the control group and the vaginal delivery group.ConclusionsIt was observed that women who birthed with vaginal or cesarean delivery had impaired somatosensory postural control. There is definitely a need for further studies with a long-term follow-up examining the effects of postural control during pregnancy and the postpartum period.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号